Rhythm Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	174.33	130.13	77.43	23.64	3.15	-
Revenue Growth (YoY)	54.92%	68.06%	227.56%	649.46%	-	-
Cost of Revenue	18.48	13.37	9.3	2.13	0.6	-
Gross Profit	155.86	116.76	68.13	21.51	2.56	-
Selling, General & Admin	175.59	144.3	117.53	92.03	68.49	46.13
Research & Development	166.48	237.96	134.95	108.63	104.13	90.45
Operating Expenses	342.07	382.26	252.48	200.66	172.61	136.58
Operating Income	-186.21	-265.5	-184.36	-179.16	-170.06	-136.58
Interest Expense	-21.42	-20.6	-13.89	-5.2	-	-
Interest & Investment Income	14.72	14.71	13.95	4.03	0.45	2.58
Other Non Operating Income (Expenses)	9.91	11.14	0.19	0.25	100	-
EBT Excluding Unusual Items	-182.99	-260.26	-184.11	-180.08	-69.61	-134
Gain (Loss) on Sale of Investments	-	-	-	-1.04	-	-
Pretax Income	-191.89	-260.26	-184.11	-181.12	-69.61	-134
Income Tax Expense	0.44	0.35	0.56	-	-	-
Net Income	-192.33	-260.6	-184.68	-181.12	-69.61	-134
Preferred Dividends & Other Adjustments	5.39	3.97	-	-	-	-
Net Income to Common	-197.71	-264.57	-184.68	-181.12	-69.61	-134
Shares Outstanding (Basic)	64	61	58	52	50	44
Shares Outstanding (Diluted)	64	61	58	52	50	44
Shares Change (YoY)	5.39%	5.76%	10.65%	5.08%	12.40%	21.15%
EPS (Basic)	-3.11	-4.34	-3.20	-3.47	-1.40	-3.04
EPS (Diluted)	-3.11	-4.34	-3.20	-3.47	-1.40	-3.04
Free Cash Flow	-109.13	-113.88	-136.2	-173.71	-146.44	-122.19
Free Cash Flow Per Share	-1.71	-1.87	-2.36	-3.33	-2.95	-2.77
Gross Margin	89.40%	89.73%	87.99%	90.98%	81.01%	-
Operating Margin	-106.81%	-204.04%	-238.10%	-757.92%	-5391.85%	-
Profit Margin	-113.41%	-203.32%	-238.52%	-766.22%	-2207.10%	-
Free Cash Flow Margin	-62.60%	-87.51%	-175.91%	-734.87%	-4642.90%	-
EBITDA	-184.76	-263.94	-182.6	-177.49	-168.9	-135.89
EBITDA Margin	-105.98%	-202.83%	-235.83%	-	-	-
D&A For EBITDA	1.45	1.56	1.76	1.67	1.16	0.69
EBIT	-186.21	-265.5	-184.36	-179.16	-170.06	-136.58
EBIT Margin	-106.81%	-204.04%	-238.10%	-	-	-
Revenue as Reported	174.33	130.13	77.43	23.64	3.15	-

Updated Nov 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q